Ongoing Results From a Dose Expansion Cohort of CYT-0851 in Combination With Capecitabine in Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity and Generally Well Tolerated Safety ProfileBusiness Wire • 10/12/23
Cyteir Therapeutics Announces Discontinuation of CYT-0851 Development Program and Planned Liquidation and DissolutionBusiness Wire • 06/30/23
Preliminary Ongoing Results with CYT-0851 in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors Show Early Clinical Activity and Generally Well Tolerated Safety ProfileBusiness Wire • 06/03/23
Cyteir Therapeutics Reports First Quarter 2023 Financial Results and Operational HighlightsBusiness Wire • 05/10/23
Cyteir Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Operational HighlightsBusiness Wire • 03/23/23
Cyteir Therapeutics Announces Prioritization of CYT-0851 Development and Extended Cash RunwayBusiness Wire • 01/19/23
Cyteir Therapeutics Reports Third Quarter 2022 Financial Results and Operational HighlightsBusiness Wire • 11/07/22
Cyteir Therapeutics Presents Poster on the Identification of Mechanism of Action of CYT-0851 at the 34th Annual EORTC-NCI-AACR SymposiumBusiness Wire • 10/12/22
Cyteir Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare ConferenceBusiness Wire • 08/31/22
Cyteir Therapeutics Reports Second Quarter 2022 Financial Results and Operational HighlightsBusiness Wire • 08/08/22
Cyteir Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Virtual ConferenceBusiness Wire • 08/01/22
CYT-0851 Phase 1 Dose Escalation Results Show Early Clinical Activity and Generally Well Tolerated Safety Profile in Advanced Solid Tumors and Hematologic MalignanciesBusiness Wire • 06/05/22
Cyteir Therapeutics to Participate in the 2022 Jefferies Healthcare ConferenceBusiness Wire • 05/31/22
Cyteir Therapeutics Reports First Quarter 2022 Financial Results and Operational HighlightsBusiness Wire • 05/05/22
Cyteir Therapeutics to Participate in the 2022 Bank of America Healthcare ConferenceBusiness Wire • 05/04/22
Cyteir Therapeutics Names Krisztina Nemenyi as Senior Vice President of Regulatory Affairs and QualityBusiness Wire • 05/03/22
Cyteir Therapeutics to Host Virtual Research and Development (R&D) Day on April 26, 2022Business Wire • 04/18/22
Cyteir Therapeutics, Inc. (CYT) CEO Dr. Markus Renschler on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/17/22
Cyteir Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Operational HighlightsBusiness Wire • 03/16/22
Cyteir Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 16, 2022Business Wire • 03/09/22
Cyteir Therapeutics Announces the Appointment of Stephen Sands to Board of DirectorsBusiness Wire • 02/24/22